MEETINGS - Molecular & Genetic Diagnostics: Profiting from Novel Diagnostics that Assess Disease Risk, Disease Presence & Treatment Response (UK) October 1999:
This article was originally published in Clinica
Executive Summary
IBC Conferences will hold a meeting on Molecular & Genetic Diagnostics: Profiting from Novel Diagnostics that Assess Disease Risk, Disease Presence & Treatment Response in London on October 4-5. Dr Uwe Bicker, executive chairman and director of Dade Behring and president of the European Diagnostic Manufacturers Association (EDMA), will present the keynote speech on growth & shift in the diagnostics industry. Representatives from companies including Roche Molecular Systems, Shield Diagnostics and Nycomed Amersham Imaging will discuss some of the latest developments in this field. For more details contact IBC in the UK. Tel: +44 20 7453 5496. Fax: +44 20 7636 6858. Website: www.ibc-uk.com/it1135
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.